We have concluded our additions of monoclonal antibodies to the hepatology website. The following fifteen drugs have been added in this batch:
Bronchodilators: Reslizumab.
Cancer Therapies: Ramucirumab, Sacituzumab govitecan, Trastuzumab, Trastuzumab deruxtecan, and Trastuzumab emtansine.
Immunosuppressants: Ravulizumab, Risankizumab, Secukinumab, Siltuximab, Tildrakizumab, Tralokinumab, Ustekinumab, and Vedolizumab.
Other: Romosozumab.
This brings our number of comedications up to 895, giving rise to 23,270 individual interactions.
